Report reveals 2021 was another bumper year for biopharma deal-making
The largest sums of capital were awarded to US biotech companies, followed by companies based in Mainland China and the UK
2021 was yet another extraordinary year for biopharma deal-making — licensing, collaborations and joint ventures — despite the reduced volume of biotech investments, according to a new report by Clarivate.
The report, Biopharma deals in review: Review of an extraordinary 2021 and expectations for the future, finds RNA, cell and gene therapies, artificial intelligence (AI), genome editing (CRISPR) and oncology-related deals dominated the landscape in 2021.
A record 1,968 deals were announced in 2021, and the total value of these ventures for which financial details were disclosed was $213.6 billion, up from $198.2 billion in 2020.
Of the past five years, 2021 saw the highest total financing and deal value. This was driven by a number of high-value transactions: 72 deals were worth at least $1 billion, for a combined value of $136.5 billion.
So what were the trends driving licensing, collaborations and joint ventures last year?
In essence, they included a maturation of deals towards co-development and co-commercialisation, as well as the increasingly global nature of deal-making.
The continued drive in oncology therapeutics and pharma companies seeking footholds in the enabling technologies underpinning next-generation treatments also shaped biopharma deals in 2021.
Several of the top deals involved co-development and co-commercialisation of assets. Capital investments are becoming a less attractive proposition as well-financed biotech companies are leaning towards deals that allow them to retain commercialisation rights and integrate their assets across the development lifecycle.
The report also identifies that biotech companies in the US were awarded the largest sums of capital, the majority of which came from private and venture sources, accounting for 67% of all funds raised worldwide.
By comparison, biotechs based in Mainland China had a 12% share of the global take, putting them in second place, while UK-based biotech companies came in third with a 9% share.
Partnerships established by companies in the Asia-Pacific (APAC) region indicate there is growing interest in accessing global markets, potentially with the goal of maximising the returns on investment beyond what can be achieved in their local markets.
According to Clarivate's Global Head of Life Sciences and Healthcare Thought Leadership, Mike Ward, while some pharma companies will still seek to acquire potential blockbuster treatments to replace existing products that are losing patent protection, others are "urgently" looking for routes into the enabling technologies being developed by biotechs.
These technologies are gene and cell therapies, genome-editing, antibody-drug conjugates, RNA technologies and AI/ML (machine learning) applications, which have gained much recent traction and are expected to underpin the next generation of transformative blockbusters.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance